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A significant limitation of rAAV vectors has been the cumbersome and technically challenging methods required for the generation of high-titer vector preparations. In many laboratories, rAAV is routinely produced using a two-plasmid transient transfection system. One plasmid contains an expression cassette for the gene of interest that is flanked by the AAV ITRs; the second plasmid encodes for AAV helper functions (rep and cap genes). rAAV is produced by co-transfection of both plasmids into an appropriate cell line (usually 293 cells) concurrent with wild-type adenovirus infection. A recent variation of this strategy calls for a third plasmid to be transfected that expresses several adenovirus early gene products (E1B, E2A, E4, VA1 RNA); this improvement apparently eliminates the need for wild-type adenovirus infection. 10 The adenoviral gene products, whether supplied by infection or plasmid transfection, are needed to create a favorable intracellular milieu for efficient AAV replication and propagation. [11] [12] [13] [14] Unfortunately, the generation of replication-competent wild-type-like AAV by non-homologous recombination has recently been shown to occur in this transfection system. 15, 16 In addition, cotransfection (or tri-transfection) methods are inherently inefficient due to the requirement for three separate 'hits' on any given cell. Another consideration is that largescale production of rAAV by transient transfection methods is likely to be difficult to adapt for large-scale manufacturing.
Our focus has been on developing systems for rAAV production that do not rely on transfection of plasmid DNAs. To that end, we and others have generated packaging cell lines that contain integrated copies of the AAV rep and cap genes 17 and cell lines that contain rep, cap and an integrated rAAV vector. 18 In lines that contain the integrated vector, all that is required for rAAV production is infection of the cells with adenovirus. However, in lines that contain only the rep and cap genes, the vector DNA must still be supplied by transfection.
In keeping with our general approach, we have now developed a system for rAAV genome delivery to a general rAAV packaging cell line that avoids plasmid transfection. Specifically, this method utilizes a HeLa-derived cell line (designated C12) that inducibly expresses AAV Rep and Cap proteins in response to adenovirus infection. 17 Plasmid DNA transfection is avoided because the rAAV genome is embedded in the E1 region of a replication-deficient recombinant adenovirus (rAd) and is delivered by direct transduction. Because HeLa cells do not supply the E1 function needed for rAd replication and rAAV production, wild-type adenovirus is added to the system to supply E1 proteins efficiently. Infectious rAAV is generated by this method, and offers an alternative to the derivation of packaging cell lines containing integrated copies of the rAAV vector.
A hybrid recombinant Ad (rAd/AAV/␤-gal) was generated that contained a rAAV vector genome positioned in the E1 region of Ad5 (rAd/AAV/␤-gal; Figure 1 ). In preliminary experiments to test for replication of the rAAV genome, 293 cells (used to supply the E1 function in trans) were infected with rAd/AAV/␤-gal and transfected with an AAV helper plasmid (pBS/Rep-Cap) that supplied the rep gene ( Figure 2, lanes 3, 4) . The appearance of distinct monomeric and dimeric rAAV replicative DNA forms in cells that received the rep gene ( Given these results, it was not surprising that qualitatively similar data were obtained when rAd/AAV/␤-gal was used to infect C12 cells (Figure 2 , lanes 7 and 8). C12 cells contain stably integrated functional copies of the AAV rep and cap genes under the control of the endogenous AAV promoters. In the absence of wild-type Ad5, no replication of either rAd/AAV/␤-gal or rAAV/␤-gal was observed since C12 cells do not contain the E1 protein of the Ad genome ( Figure 2, lanes 7) . Normal HeLa cells (from which C12 cells were derived) did not support rAAV/␤-gal replication (Figure 2 , lanes 5 and 6).
We next tested the ability of rAd/AAV/␤-gal to produce infectious rAAV/␤-gal in the context of C12 cells. C12 cells were coinfected with rAd/AAV/␤-gal and Ad5 or rAd/AAV/␤-gal alone, and a clarified cell lysate was prepared that would potentially contain infectious rAAV particles. These lysates were then used to infect naive C12 cells in the presence of wild-type Ad (Figure 3a , lanes 4 and 5). Monomeric and dimeric rAAV-replicative DNA 
) (lane 4). Lanes 5 and 6, normal HeLa cells were infected with rAd/AAV/␤-gal (MOI, 10), and transfected with pBS/rep-cap (lane 5); or infected with wild-type Ad5 (MOI, 10) (lane 6). Lanes 7 and 8, C12 cells were infected with rAd/AAV/␤-gal (MOI, 10) and either mock-treated (lane 7); or infected with wild-type Ad5 (MOI, 10) (lane 8). Because C12 cells contain stably integrated functional copies of pBS/rep-cap, transfection of the plasmid was not required (na, not applicable).
forms were detected in the presence of Ad5, thereby indicating that infectious rAAV particles had been formed and passed on to the naive C12 cells. To confirm infectious rAAV/␤-gal production further, 293 cells were transduced with a portion of the same lysate, and ␤-galactosidase expression was detected in a significant fraction of the 293 cell monolayer by X-gal staining ( Figure 3b ). Importantly, we did not detect wild-type AAV in this rAAV/␤-gal preparation. This determination was made by passing rAAV/␤-gal on to normal HeLa cells in the presence of adenovirus and then testing for replicative forms of wild-type AAV in Hirt DNA by Southern blot analysis. The level of sensitivity in this experiment was one wild-type AAV infectious particle in 2 × 10 6 rAAV/␤-gal infectious particles. Because conditions in the initial experiments described above had been arbitrarily chosen, we next turned our attention to defining the effects of rAd MOI on rAAV production. Our hope was that adding increasing amounts of rAd/AAV/␤-gal (and thereby rAAV genome copies) would increase rAAV production. To test this hypothesis, C12 cells were co-infected with varying amounts of rAd/AAV/␤-gal and a constant amount of Ad5, and then the amount of infectious rAAV/␤-gal pro- duced was determined ( Figure 4) . Surprisingly, the yield of rAAV infectious particles was inversely proportional to the amount of rAd/AAV/␤-gal used to infect the C12 cells. In fact, at an rAd/AAV/␤-gal MOI of 100, less than 100 IU of rAAV (the limit of detection) was found. We also noted that the total yield of infectious virus was approximately 20-fold lower than that generated by transient transfection (Figure 4 ).
Figure 3 Production of infectious rAAV from C12 cells following rAd/AAV/␤-gal and Ad5 coinfection. (a) C12 cells were treated as indicated in the
Given these unexpected results, we were prompted to examine another variable that might influence rAAV production in this system, namely the timing of the Ad infections. We reasoned that since rAd/AAV/␤-gal infection appeared to inhibit rAAV/␤-gal production (and therefore, potentially rep gene expression), it might be possible to circumvent this effect by stimulating rep synthesis first by infecting with Ad5 before the addition of rAd/AAV/␤-gal. Three sets of parallel experiments were performed in C12 cells wherein: (1) infection with rAd/AAV/␤-gal preceded Ad5 infection; (2) rAd/AAV/␤-gal and Ad5 were introduced simultaneously (co-infection as in Figure 4) ; and (3) infection with Ad5 preceded rAd/AAV/␤-gal infection ( Figure 5) . The initial observations shown in Figure 4 were confirmed. When rAd/AAV/␤-gal infection preceded Ad5 infection, or both were introduced simultaneously, there was a dramatic inhibitory effect on rAAV/␤-gal production at the highest MOI (100) of rAd/AAV/␤-gal. Again, the addition of more Ad5 did not alter this inhibitory effect; however, during co-infection, more Ad5 did increase yields at the lower MOI (1 and 10) of rAd/AAV/␤-gal ( Figure 5 ). Interestingly, when Ad5 infection preceded rAd/AAV/␤-gal infection, rAAV/␤-gal yields increased at all MOI of rAd/AAV/␤-gal, although there was still a demonstrable inhibitory effect at an MOI of 100.
Having shown a clear correlation of rAAV/␤-gal yield with the timing of Ad infection, we asked whether Rep and Cap protein expression were also affected in a similar manner. As shown in Figure 6 , this was indeed the case. Rep and Cap protein expression were highest when Ad5 infection preceded rAd/AAV/␤-gal infection and was maximal when the Ad5 MOI was 100 ( Figure 6 , lane 8 in a and b). These data were entirely consistent with the yields of infectious rAAV/␤-gal shown in Figure 5 . Moreover, quantitative analyses of rep mRNA levels generated under the various conditions also correlated with 
Clarified lysates were prepared and incubated at 56°C for 1 h to inactivate contaminating adenovirus. This material was then serially diluted and used to co-infect naive C12 cells along with Ad5 (MOI, 20). Cells were fixed at 36 h after infection, stained with X-gal reagent, and the titer determined by counting blue staining cells. 17 Two control experiments (labeled 293 and C12) were performed. C12 cells were transfected with plasmid pAAV/CMV/␤-gal 17 and 293 cells were co-transfected with pAAV/CMV/␤-gal and pBS/rep-cap 17 (both in the presence of Ad5). The y-axis represents the total yield of infectious virus from a single well of a six-well plate. All reported values represent the average of three independent experiments (error bars represent s.d.). the infectious virus yield and Rep protein expression (data not shown).
In association with higher levels of Rep expression in those experiments where Ad5 infection preceded rAd/AAV/␤-gal infection, we also expected to find increased levels of rAAV replicative DNA forms. Genome replication of rAAV was examined by Southern blot hybridization of low molecular weight DNA isolated 24 and 48 h after infection of C12 cells. As expected, rAAV replication was higher when Ad5 infection preceded rAd/AAV/␤-gal infection (Figure 7) . Again, these data were consistent with the notion that Ad5 infection of C12 cells induces rep expression to levels high enough to overcome the inhibitory effects of rAd/AAV/␤-gal infection.
Thus, in the system we have described herein, rAAV yield appears to correlate directly with the level of rep and cap gene expression. These data stand in contrast to previous work in transient transfection systems where enhanced rep levels were achieved by driving rep expression off strong constitutive promoters. 19, 20 Interestingly, in these studies, the reported yields of rAAV were lower than when rep was expressed from the endogenous p5 promoter. Moreover, translational attenuation of p5-derived Rep proteins (the p5 ATG was mutated to ACG) was reported to increase rAAV titers relative to the native p5 promoter sequence. 20 Taken together, these data imply that regulated rep expression is probably a requirement Figure 4 .
Figure 5 Order of infection and MOI of rAd/AAV/␤-gal and Ad5 significantly influences rAAV production. Three sets of parallel experiments were performed in C12 cells wherein: (1) infection with rAd/AAV/␤-gal preceded Ad5 infection by 15 h; (2) rAd/AAV/␤-gal and Ad5 were introduced simultaneously; and (3) infection with Ad5 preceded rAd/AAV/␤-gal infection by 15 h. The MOI for each virus varied as indicated in the graph. Titers were determined from cell lysates as described in

A control experiment (labeled C) was performed by transfecting C12 cells with plasmid pAAV/CMV/␤-gal 17 in the presence of Ad5. The titers (shown on the y-axis) represented the total yield of infectious virus from a single well of a six-well plate. All reported values represent the average of three independent experiments (error bars represent s.d.).
for efficient rAAV production and that excess Rep protein might inhibit rAAV synthesis, particularly when rep sequences are supplied by transfected plasmid DNA.
One possible explanation for the apparent discrepancy between the effect of rep levels on rAAV yields using the two production approaches (stable cell lines versus plasmid transfection) might involve the relative rep and cap gene copy number present in each system. Based on Southern hybridization reconstruction experiments, we have estimated that the C12 line contains five to 10 integrated copies of the rep-cap sequence (unpublished data). This is in contrast to transfection methods which would be expected to introduce significantly greater rep-cap gene copy numbers into the recipient target cell (10 2 -10 3 copies). Therefore, plasmid transfection might actually introduce a relative excess of rep copies into cells that could result in cytostatic or cytotoxic effects on cellular macromolecular synthesis. In our packaging cell line, the opposite model might be operative. While there are only five to 10 copies of the rep gene present in the C12 cell line, following adenovirus infection, the rep-cap DNA copy number increases by approximately 60-fold. Rep-cap gene amplification was detected by Southern blot hybridization of the unit length plasmid restriction fragment (10 kb) after SpeI digestion (a single cutter, data not shown). ITR independent rep-cap amplification has not been previously reported, but the AAV p5 promoter does contain a functional trs. 21 One possibility is that following rep-mediated nicking at the p5 trs, nearby cellular ori sequences (using a host polymerase) might substitute for a AAV origin of replication (ITR). We also note that this rep-cap gene amplification phenomenon was not observed following transient cotransfection methods. Hence, rep-cap gene copy number appears to increase in a regulated fashion over the course of rAAV synthesis. Elevated Cap protein levels are reported to correlate with optimal rAAV yields using transfection approaches, 19 and recent data also suggest that Cap protein levels must reach a critical intracellular concentration for efficient capsid formation. 22 We also observed efficient Cap protein synthesis in C12 cells when Ad5 infection preceded rAd/AAV/␤-gal infection (Figures 5  and 6 ). Interestingly, the Rep proteins derived from the spliced RNAs predominate (Rep40 and Rep68) under the optimal conditions in these experiments. These same Rep proteins have been shown to co-localize to cells actively expressing capsid proteins, while Rep78 and Rep52 protein do not. 23 The molecular basis for this biased expression in C12 cells is not understood at the present time.
Recently, adenovirus MOI has been identified as a factor that causes increased AAV capsid synthesis 19, 23 and our data are consistent with this observation. We detected increasing Cap protein synthesis in response to increasing doses of Ad5. It is likely that increased adenovirus gene products resulted in more efficient AAV help through processes involved in post-transcriptional stabilization of AAV mRNA, increased cytoplasmic transport of AAV transcripts, and enhanced translation of viral messages. It is interesting to note that rAAV generated by plasmid co-transfection demonstrated very little sensitivity to Ad5 input MOI. In contrast, stable producer cell lines routinely show titer augmentation by a factor of 100 when Ad5 inputs are varied from one to 100 (unpublished observations).
One of the most interesting aspects of this study was the discovery that rAd/AAV/␤-gal at a high MOI can actually inhibit rAAV production from a packaging cell line. One possible explanation involves the unintended introduction of too many copies of E1-deficient recombinant adenoviral genomes. As these E1-defective genomes replicate in the presence of Ad5, the intracellular pool of free E1 adenovirus gene products may become limited and as a result, lower levels of rep p5 transactivation may occur. 24, 25 In addition or alternatively, the ITR sequences present in the replicating rAd/AAV replicon might act to physically sequester Rep proteins on the ITR rep binding sites, potentially causing a failure of these proteins to activate p5, p19, and p40 transcription efficiently. Regardless of the inherent mechanism, it is clear that Ad5 infection has to precede (by 12-18 h) the introduction of the rAd/AAV replicon, presumably to allow sufficient rep synthesis to occur before replication of the E1-deficient rAd genome.
Two other groups have reported the generation of similar rAd/AAV hybrid molecules. 26, 27 However, neither group used the hybrid genomes to generate infectious rAAV from AAV packaging cell lines. In these studies, AAV helper components were supplied by transfection 26 or polylysine-dependent conjugation to the outer adenovirion capsid. 27 Our current effort extends this earlier work by now showing that rAd/AAV hybrids can be used in conjunction with a packaging cell line system to generate infectious rAAV. In our hands, the current levels of infectious rAAV production using this system do not appear to exceed that achieved by transient transfection (293 or C12 cells) methods. Additionally, the yield of infectious rAAV/␤-gal obtained using this dual adenovirus infection method (10 IU per cell) is approximately three-fold lower than rAAV yields produced using a previously published stable producer cell line (H44, Clark et al). 18 It seems likely that additional optimization of this system or similar ones based on superior packaging cell lines will lead to higher levels of rAAV production. One primary advantage of a universal packaging cell line (like C12) is that its use obviates the need to identify repeatedly optimal producer cell lines. The proposed method requires the generation of an E1-deleted adenovirus vector for each new rAAV vector desired. Recombinant E1-deleted adenoviruses are straightforward to isolate and can be grown to high titer in 293 cells. Moreover, this C12/dual adenovirus infection method would be amen- able to the simultaneous construction of multiple rAAV vectors, once the cognate recombinant adenoviruses were isolated. Importantly, both cell line-based methods are amenable to large-scale manufacturing processes, and appear to be free of contaminating wild-type AAV at the level of detection of our assays (р1 wt-like IU/10 6 rAAV IU).
